6 completed, 1 terminated, 1 unknown, 1 withdrawn. 9 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Polypoidal Choroidal Vasculopathy: new trials by email Literature Review of Polypoidal Choroidal Vasculopathy trials Research Report on Polypoidal Choroidal Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Zimura, Eylea - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Withdrawn | Ophthotech Corporation | 2018-11-01 | 2024-02-21 | |
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose - Polypoidal Choroidal Vasculopathy | Phase 2 / Phase 3 | Terminated | Sun Yat-sen University | 5 | 2018-08-01 | 2019-09-19 |
| A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Avacincaptad Pegol - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Completed | Ophthotech Corporation | 4 | 2015-03-12 | 2025-03-20 |
| Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 2.0 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2011-09-01 | 2022-12-12 |
| Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy ranibizumab 2.0mg - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Unknown | Retina Consultants of Hawaii | 20 | 2010-11-01 | 2010-11-25 |
| Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) high-dose ranibizumab, ranibizumab - PCV, Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Hawaii Pacific Health | 24 | 2010-11-01 | 2017-10-09 |
| Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) fosbretabulin, Saline - Polypoidal Choroidal Vasculopathy | Phase 2 | Completed | Mateon Therapeutics | 20 | 2009-07-01 | 2011-11-01 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia | Phase 1 / Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 18 | 2007-05-01 | 2012-10-25 |
| Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 0.3 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2006-05-01 | 2019-04-16 |
Choroidal Neovascularization (2) · Myopia, Degenerative (1) · Pseudoxanthoma Elasticum (1) · Retinal Telangiectasis (1) · Vascular Diseases (1) · Vitelliform Macular Dystrophy (1) · von Hippel-Lindau Disease (1)
Choroid Diseases (9) · Eye Diseases (9) · Metaplasia (9) · Neovascularization, Pathologic (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Uveal Diseases (9) · Choroidal Neovascularization (7) · Cardiovascular Diseases (2) · Abnormalities, Multiple (1) · Angiomatosis (1) · Ciliopathies (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1)
Ranibizumab (7) · aflibercept (2) · Bevacizumab (1) · Sodium Chloride (1) · combretastatin (1) · fosbretabulin (1)
Ophthotech Corporation (2) · Southeast Retina Center, Georgia (2) · Hawaii Pacific Health (1) · Manhattan Eye, Ear & Throat Hospital (1) · Mateon Therapeutics (1) · Retina Consultants of Hawaii (1) · Sun Yat-sen University (1)
United States (8) · China (1) · Hong Kong (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Dennis M. Marcus, M.D. (2) · Gregg T Kokame, MD, MMM (2) · Lawrence A. Yannuzzi, MD (1) · Lin Lu, MD, phD (1)
PMID 14557174, PMID 16897221, PMID 19726427, PMID 22426346, PMID 22990319, PMID 23352196, PMID 25646029, PMID 30957581